Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8236 to 8250 of 8914 results

  1. Rapid tranquillisation in mental health settings: promethazine hydrochloride (ESUOM28)

    This evidence summary has been updated and replaced by NICE guideline NG10.

    Withdrawn advice

  2. Chronic pain: oral ketamine (ESUOM27)

    This evidence summary has been updated and replaced by NICE guideline NG193.

    Withdrawn advice

  3. Scleroderma: oral mycophenolate (ESUOM32)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Withdrawn advice

  4. Difficult-to-treat scabies: oral ivermectin (ESUOM29)

    November 2024: This evidence summary has been withdrawn because licensed products are now available.

    Withdrawn advice

  5. Cystic fibrosis: long-term azithromycin (ESUOM37)

    This evidence summary has been updated and replaced by NICE guideline NG78.

    Withdrawn advice

  6. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Withdrawn advice

  7. Systemic lupus erythematosus: oral mycophenolate (ESUOM36)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Withdrawn advice

  8. Interstitial cystitis: oral pentosan polysulfate sodium (ESUOM43)

    This guidance has been updated and replaced by NICE technology appraisal guidance 610.

    Withdrawn advice

  9. Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Withdrawn advice

  10. Management of aggression, agitation and behavioural disturbances in dementia: valproate preparations (ESUOM41)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Withdrawn advice

  11. Postural hypotension in adults: midodrine (ESUOM5)

    This evidence summary has been updated and replaced by NICE evidence summary: new medicines 61.

    Withdrawn advice

  12. Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  13. Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Withdrawn advice

  14. Pulmonary hypertension in neonates: sildenafil (ESUOM51)

    This evidence summary has been withdrawn following updated information in the summary of product characteristics on the off-label use of sildenafil (Revatio) in neonates with persistent pulmonary hypertension of the newborn.

    Withdrawn advice

  15. Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Withdrawn advice